Trial reportEuropean journal of endocrinology2013
Primary hyperparathyroidism and metabolic risk factors, impact of parathyroidectomy and vitamin D supplementation, and results of a randomized double-blind study.
Trial report in European journal of endocrinology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Vitamin D Supplementation After Successful Parathyroid Surgery for Primary Hyperparathyroidism
Insulin Resistance in Primary Hyperparathyroidism, a Non-classical Manifestation
Who cites it
19 citing papers in PubMed, 51 citations in OpenAlex.
- Sex differences in the clinical presentation and complications of primary hyperparathyroidism: insights from a single-center cohort study.Endocrine · 2026Article
- Bone metabolism in primary hyperparathyroidism.Wiener klinische Wochenschrift · 2026Review
- Parathyroid diseases and metabolic syndrome.Journal of endocrinological investigation · 2023Review
- Effect of Parathyroidectomy on Metabolic Homeostasis in Primary Hyperparathyroidism.Journal of clinical medicine · 2022Article
- Assessment of insulin resistance in patients with primary hyperparathyroidism before and after Parathyroidectomy.Endocrinology, diabetes & metabolism · 2021Article
- [The clinical practice guidelines for primary hyperparathyroidism, short version].Problemy endokrinologii · 2021Review
- Double-counting of effect sizes and inappropriate exclusion of studies in "The influence of vitamin D supplementation on IGF-1 levels in humans: A systematic review and meta-analysis".Ageing research reviews · 2021Article
- Vitamin D Status and Its Correlation With Anthropometric and Biochemical Indicators of Cardiometabolic Risk in Serbian Underground Coal Miners in 2016.Frontiers in nutrition · 2021Article
- Lipoadenoma of the Parathyroid Gland: Characterization of an Institutional Series Spanning 28 Years.Endocrine pathology · 2020Article
- The Endocrine Role of Bone in Cardiometabolic Health.Current nutrition reports · 2019Review
- The effect of surgery on fat mass, lipid and glucose metabolism in mild primary hyperparathyroidismEndocrine connections · 2018Article
- Article
- Contemporary Medical Management of Primary Hyperparathyroidism: A Systematic Review.Frontiers in endocrinology · 2017Review
- Plasma Parathyroid Hormone Is Independently Related to Nocturnal Blood Pressure in Hypertensive Patients: The Styrian Hypertension Study.Journal of clinical hypertension (Greenwich, Conn.) · 2016Article
- Diffuse parathyroid hormone expression in parathyroid tumors argues against important functional tumor subclones.European journal of endocrinology · 2016Article
- Visceral adiposity is a predictor of parathyroid hormone levels in healthy adults.Journal of endocrinological investigation · 2016Article
- High prevalence of metabolic syndrome in a mestizo group of adult patients with primary hyperparathyroidism (PHPT).BMC endocrine disorders · 2015Article
- Tumour nuclear oestrogen receptor beta 1 correlates inversely with parathyroid tumour weight.Endocrine connections · 2015Article
- Confounded complexity: vitamin d, parathyroid hormone, and metabolic syndrome in peritoneal dialysis.Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVitamin D insufficiency may increase the risk for cardio metabolic disturbances in patients with primary hyperparathyroidism (PHPT).
objectiveTo analyze the vitamin D status and indices of the metabolic syndrome in PHPT patients and the effect of vitamin D supplementation after parathyroid adenomectomy (PTX). DESIGN AND
methodsDouble-blinded, randomized clinical trial (ClinicalTrials.gov identifier: NCT00982722) performed at Karolinska University Hospital, Sweden, April 2008 to November 2011. One hundred and fifty consecutive patients with PHPT (119 women) were randomized after PTX, 75 to oral treatment with calcium carbonate 1000 mg daily and 75 to calcium carbonate 1000 mg and cholecalciferol 1600 IU daily over 12 months. Changes in metabolic profile and ambulatory blood pressure (BP) were analyzed. Main outcome measures were changes in metabolic factors, BP, and body composition.
resultsThe 25-hydroxyvitamin D (25-OH-D)-level was <50 nmol/l in 76% of the patients before PTX. After PTX, glucose, insulin, and IGF1 decreased, while the 25-OH-D and the IGF-binding protein 1 increased and remained unchanged at follow-up after study medication. One year of vitamin D supplementation resulted in lower parathyroid hormone (PTH) (40 (34-52) vs 49 (38-66) ng/l) and higher 25-OH-D (76 (65-93) vs 49 (40-62) nmol/l; P<0.05). Other laboratory parameters were stable compared with after PTX. Systolic BP decreased and total bone mineral content increased in both groups.
conclusionExcept for the lowering of the PTH level, no additive effect of vitamin D supplementation was seen. However, PTX proved effective in reducing insulin resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.